News of Note—CSL’s flu vaccine sales, Inovio and more

non
In this week's news of note, sales of CSL's Flucelvax quadrivalent flu shot were up 43%. (Pixabay)

Here is some other vaccine news of note for the week:

> Sales of CSL’s Flucelvax quadrivalent flu vaccine were up 43% for the six months leading up to December. Brisbane Times article

> Inovio and The Wistar Institute are collaborating on two vaccines against tuberculosis and malaria, with total grants of more than $4.6 million from the Bill & Melinda Gates Foundation and the NIH. Release

> Three crisis management experts analyzed Sanofi Pasteur’s response to the Dengvaxia situation in the Philippines. The Wall Street Journal commentary

> FDA Commissioner Scott Gottlieb, M.D., said his agency is working with the CDC to understand why protection offered by this year’s flu vaccine is less than optimal. Tweet

> To cope with flu vaccine shortage this year, Hong Kong health officials are considering using shots intended for the southern hemisphere. South China Morning Post article